
For Industry.
Cooperating in finding solutions for patients.

WHAT CAN EMHA DO FOR THE INDUSTRY.
Cooperating in finding solutions for patients.
Working together is the only way to find effective and lasting solutions for migraine sufferers.
By encouraging research, supporting projects and working to distribute reliable information, we can achieve a better quality of life for all patients living with migraine.

EMHA PROJECTS
Raising awareness to change the future under #TheMigraineMovement

Stigma survey 2023
Migraine & Stigma Survey 2023 In 2023, the EMHA conducted a comprehensive pan-European digital survey answered by 4.210 people across 17 countries. In order to examinate the origins of stigma surrounding migraine, its impact on patients, and their need for better understanding and support. The survey covers various topics such as patients’ ease in sharing

Access to care survey 2021
The EMHA worked along KPMG on a market research to understand the patient journey and burden of disease for migraine in 12 countries. The Access to care survey 2021 has shown insightful results on the patients’ access to treatment and care in each of their country. Summary of the โAccess To Care IIIโ survey results

Women at work
In 2018 EMHA organised a survey among migraine patients working in 7 EU countries (Ireland, Italy, France, Germany, Portugal, Spain and United Kingdom.
The survey shed light on how women have to juggle between migraine attacks and work.

The Migraine Assistant
After launching The Migraine Movement Manifesto, from EMHA, we set the goal to inform the largest amount of European migraine sufferers about the existence of that movement, born with the aim of giving them visibility, answers and support.

Explaining Migraine
We realized that the words we normally use to describe our relationship with migraine simply fall short to convey the true feeling behind. Words like โpainโ or โhorrorโ, commonly used to describe a migraine, ended up being generic adjectives that linked our disease to a simple headache.

The Missing Lesson
The lack of medical training is the main barrier for an accurate diagnosis when a possible migraine patient first visits a doctor. In the world, only 4 hours of migraine are studied in medical training.
COLLABORATIVE SUPPORTERS GUIDELINES
Working with the pharmaceutical and biotech industries.
Cooperate to improve the life quality of all the migraine sufferers community.
Abbvie

Curelator

Grunenthal

Lilly

Lundbeck

Novartis

Sanofi

Teva

COLLABORATORS
We have the support of all of them.

VISIT AHMA
ANNUAL REPORT
EMHA Activities Report 2022
EMHAโs agenda of 2022 was filled with trips, meetings and events that put migraine on the agenda of Europeanโs and worldwide organizations and policy makers.